This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Crinetics' Phase 2 Results of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Ticker(s): CRNX

Who's the expert?

Institution: University of São Paulo Medical School – Division of Pediatric Endocrinology 

  • Associate professor in pediatric endocrinology at the University of São Paulo Medical School (FMUSP) and a recognized clinical expert in hereditary and endocrine disorders in children, with a long academic and clinical track record.

  • Extensive clinical experience leading care for infants, children, and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency and related hyperandrogenic endocrine conditions; she also champions newborn screening initiatives for CAH in Brazil.

  • Research portfolio includes molecular diagnostics, therapeutic strategies, and long-term outcomes in CAH and endocrine conditions, as evidenced by numerous publications and contributions to international studies on neonatal screening and growth hormone therapy.

Interview Goal
To gain a deeper understanding of Atumelnant as a potential treatment for Congenital Adrenal Hyperplasia

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.